Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.
SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?
Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.
Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?
Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.